ASSOCIATION OF CLINICAL RESPONSE WITH SURVIVAL AND QUALITY OF LIFE (QOL) AFTER CARFILZOMIB AND DEXAMETHASONE (KD56) TREATMENT IN THE PHASE 3 ENDEAVOR TRIAL

EHA Library, David Siegel, 216431

MINIMAL RESIDUAL DISEASE NEGATIVITY AFTER MOLECULARLY TARGETED VENETOCLAX THERAPY OF SECONDARY PLASMA CELL LEUKEMIA WITH TRANSLOCATION T(11;14)

EHA Library, Gabor Mikala, 216432

ASSESSMENT OF PNEUMOCOCCAL VACCINATION RESPONSE IN MULTIPLE MYELOMA

EHA Library, Marc Ellis, 216433

THE DETERMINATION OF FACTORS AFFECTING ON THE PROGRESSION-FREE SURVIVAL OF MULTIPLE MYELOMA PATIENTS

EHA Library, Andrei Garifullin, 216434

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 216435

EARLY RELAPSE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION IS A MAJOR PREDICTIVE FACTOR OF LOWER OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS

EHA Library, Adriana Roque, 216436

PROGNOSTIC SIGNIFICANCE OF THE CHROMOSOME 1 ABNORMALITIES IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Jelena Bila, 216437

GOOD OUTCOMES USING ACTIVE TREATMENT WITH NOVEL AGENTS IN ELDERLY MYELOMA PATIENTS

EHA Library, Nadishani Ediriwickrama, 216438

SURVIVAL OF RELAPSED MYELOMA PATIENTS WITH A SECOND AUTOGRAFT: LOCAL EXPERIENCE

EHA Library, Craig Hendry, 216439

PHASE 2 STUDY FOR CARFILZOMIB PLUS ELOTUZUMAB PLUS DEXAMETHASONE FOR MYELOMA PATIENTS RELAPSED AFTER 1-3 PRIOR TREATMENT LINES

EHA Library, Raija Silvennoinen, 216440

ORAL CYCLOPHOSPHAMIDE’S ADDITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT

EHA Library, Laura Cesini, 216441

DETECTION OF ASYMPTOMATIC FEMORAL HEAD AVASCULAR NECROSIS ON ROUTINE WHOLE BODY MRI IN PATIENTS WITH MULTIPLE MYELOMA PROVIDES OPPORTUNITIES FOR JOINT PRESERVATION.

EHA Library, Priya Sriskandarajah, 216442

ELIGIBILITY CRITERIA FOR CLINICAL TRIALS AND COMORBIDITY AS PREDICTORS OF CHEMOTHERAPY DOSE ADJUSTMENT IN PATIENTS WITH MULTIPLE MYELOMA.

EHA Library, Ernesto Pérez Persona, 216443

MONTELUKAST AND GEMFIBROZIL WHEN ADDED TO BORTEZOMIB BASED THERAPY INDUCES RAPID RESPONSE IN PATIENTS WITH REFRACTORY AND HIGH RISK DISEASE.

EHA Library, Stephen O'Mara, 216444

EARLY PARAPROTEIN REDUCTION AND RESPONSE TO FIRST-LINE TREATMENT IN MULTIPLE MYELOMA

EHA Library, Moritz Binder, 216445

PROGNOSTIC SIGNIFICANCE OF HEAVY/LIGHT CHAIN RATIO IN INTACT IMMUNOGLOBULIN MULTIPLE MYELOMA PATIENTS-PRELIMINARY RESULTS

EHA Library, Ioannis Kakkas, 216446

EFFICACY, SAFETY AND TOLERABILITY OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) REGIMEN IN RR/MM

EHA Library, Valeria Calafiore, 216447

HIGH IMPLEMENTATION ADHERENCE TO LENALIDOMIDE IN MULTIPLE MYELOMA

EHA Library, IRINA AMITAI, 216448

RETROSPECTIVE AUDIT OF BISPHOSPHONATE USE IN MULTIPLE MYELOMA PATIENTS IN TWO DISTRICT GENERAL HOSPITALS AND FRACTURE CONSENSUS

EHA Library, Zahbia Saleem, 216449

BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE

EHA Library, Claudio Cerchione, 216450

POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 216451

BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 216452

A COMPARATIVE ANALYSIS OF FREE LIGHT CHAIN CONCENTRATIONS IN SERUM AND CEREBROSPINAL FLUID FOR PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY MYELORADICULOPATHY

EHA Library, Елена Трифонова, 216453

SALVAGE THERAPY WITH POMALIDOMIDE-BASED REGIMEN IN RELAPSED/REFRACTORY MYELOMA. EFFICACY, AND SAFETY RESULTS.

EHA Library, Maialen Sirvent Auzmendi, 216454

SPLENIC INVOLVEMENT IN AL AMYLOIDOSIS: A CAUSE FOR PANCYTOSIS

EHA Library, Andreea Jercan, 216455

MULTIPLE MYELOMA AND INFECTIONS IN THE “NOVEL AGENTS ERA”: A REAL-LIFE RETROSPECTIVE UNICENTRIC EXPERIENCE.

EHA Library, Maria Stefania Infante, 216456

EFFECTIVENESS OF BENDAMUSTINE IN RELAPSED OR REFRACTORY AL AMYLOIDOSIS

EHA Library, Nathalie Forgeard, 216457

IMPACT OF IMPROVEMENT IN RENAL FUNCTION AND WAITING TIME BEFORE INDUCTION THERAPY ON SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Nikolett Wohner, 216458

FREQUENCY AND CAUSES OF NOT RECEIVING SUCCESSIVE LINES OF TREATMENT IN REFRACTORY MULTIPLE MYELOMA: A CROSS-SECTIONAL STUDY.

EHA Library, Alicia Senín, 216459

MONOCLONAL GAMMOPATHY AND TRANSTHYRETIN AMYLOIDOSIS.

EHA Library, Ana Alarcon, 216460

RISK FACTORS FOR EARLY MORTALITY IN MULTIPLE MYELOMA WITH DIFFERENT SURVIVAL TIME CUT-OFF POINTS: REAL-LIFE DATA

EHA Library, Seda Balaban, 216462

MONTELUKAST COMBINED WITH THE LIPID LOWERING DRUG GEMFIBROZIL REVERSES RESISTANCE TO COMBINATION CHEMOTHERAPY IN PATIENTS WITH MULTIPLE MYELOMA. RESULTS OF PROSPECTIVE PHASE 1 / 2 CLINICAL TRIAL.

EHA Library, Stephen O'Mara, 216463

NORWEGIAN REAL-LIFE EXPERIENCE OF PREAPPROVAL CARFILZOMIB THROUGH COMPASSIONATE USE NAMED PATIENT PROGRAM (NPP) FOR RELAPSING/REFRACTORY MYELOMA (RRMM)

EHA Library, Ina Haarstad, 216464

DOES ASYMPTOMATIC D-DIMER ELEVATION PREDICT THROMBOSIS IN PATIENTS ON IMMUNOMODULATORY DRUGS IN MULTIPLE MYELOMA: REAL-LIFE DATA

EHA Library, Seda Balaban, 216465

EFFICACY OF NEW DRUGS PRIOR TO SINGLE OR TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. A SINGLE CENTER EXPERIENCE

EHA Library, Sara Grammatico, 216466

DEGREE OF VULNERABILITY IN PATIENTS WITH MULTIPLE MYELOMA: A COMPARATIVE STUDY BETWEEN THE APPLICATION OF CLINICAL JUDGMENT AND THE SCALE OF ASSESSMENT (GA SCALE)

EHA Library, Eugenia Abella, 216468

BLEEDING AND THROMBOTIC COMPLICATIONS IN PLASMA CELL DISORDERS IN THE "NOVEL AGENTS ERA": RISK FACTORS, OUTCOME ,PROGRESSION AND STRATEGIES OF PREVENTION.A REAL-LIFE MONOCENTRIC RETROSPECTIVE ANALYSIS

EHA Library, Lorenza Torti, 216469

OUTCOME OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH PCCD (POMALIDOMIDE - CYCLOPHOSPHAMIDE-CLARITHROMYCIN - LOW DOSE DEXAMETHASONE) IN THE REAL-LIFE SETTING

EHA Library, Rafael Rios-Tamayo, 216470

REAL WORLD DATA OF AGE RELATED CYTOGENETIC ABNORMALITY DISTRIBUTION IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS: SINGLE CENTRE EXPERIENCE FROM THE UNITED KINGDOM

EHA Library, Jennifer Tam, 216471

OUTCOME OF PATIENTS WITH MULTIPLE MYELOMA AND RENAL FAILURE IN ERA OF NOVEL AGENTS- EXPERIENCE OF A TERTIARY CARE CENTRE FROM NORTHERN INDIA.

EHA Library, Nitin Gupta, 216472

EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB MONOTHERAPY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Rimke Oostvogels, 216474

CLINICAL FEATURES AND OUTCOMES OF SOLITARY PLASMACYTOMAS: SINGLE-CENTER EXPERIENCE FROM TURKEY

EHA Library, Yusuf Ulusoy, 216475

RESPONSE TO INDUCTION THERAPY IN MULTIPLE MYELOMA PATIENTS; A SINGLE CENTRE EXPERIENCE.

EHA Library, Munira Borhany, 216476

SERVICE DELIVERY OF APPROVED DARATUMUMAB TREATMENT FOR RELAPSED MYELOMA; CHALLENGES OF NORMAL IMMUNOGLOBULIN AND UNAFFECTED FREE LIGHT CHAIN SUPPRESSION, ESPECIALLY WHEN ASCT IS INCLUDED.

EHA Library, Raymond Powles, 216477

LIGHT-CHAIN DEPOSITION DISEASE: DIAGNOSIS AND TREATMENT CHALLENGES. A SINGLE CENTER EXPERIENCE

EHA Library, SORINA BADELITA, 216478

BULKY EXTRAMEDULLARY SOFT-TISSUE PLASMACYTOMAS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE FROM NORTH INDIA

EHA Library, Uttam Kumar Nath, 216479

MYC REARRANGEMENT IN COHORT OF NEWLY DIAGNOSED SLOVENIAN MM PATIENTS

EHA Library, Helena Podgornik, 216480

MAINTENANCE TREATMENT WITH THALIDOMIDE AFTER FRONTLINE BORTEZOMIB-BASED REGIMENS IN TRANSPLANTATION INELIGIBLE PATIENTS WITH MYELOMA MULTIPLE (MM). EXPERIENCE OF REAL LIFE.

EHA Library, Dunia De Miguel Llorente, 216481

CT AND MRI MAY RESULT IN OVERDIAGNOSIS OF SKELETAL DISEASE IN MULTIPLE MYELOMA

EHA Library, Anders Erik Astrup Dahm, 216482

RENAL SALVAGE WITH BORTEZOMIB / CYCLOPHOSPHAMIDE / DEXAMETHASONE INDUCTION THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL INSUFFICIENCY: A SINGLE-CENTER STUDY FROM NORTH INDIA

EHA Library, Uttam Kumar Nath, 216483

ANALYTICAL CRITICALITIES ASSOCIATED TO DIFFERENT METHODS FOR SERUM FREE LIGHT CHAIN DETECTION: IMPACT ON THE INTERNATIONAL MYELOMA WORKING GROUP (IMWG) CRITERIA DEFINING SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Katja Weisel, 216484

POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN THE TREATMENT OF ASIAN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA (RRMM) WHO ARE PREVIOUSLY REFRACTORY TO LENALIDOMIDE–A TRIAL BY THE ASIAN MYELOMA NETWORK (AMN)

EHA Library, Wj Chng, 216485

INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA IN A LARGE NATIONWIDE HEALTH PLAN IN ISRAEL

EHA Library, Clara Weil, 216486

YOUNG ADULTS WITH MULTIPLE MYELOMA – UNVEILING A DIFFERENT SPECTRUM IN A RESOURCE CONSTRAINED SETTING

EHA Library, Sumeet Mirgh, 216487

AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA AND RENAL FAILURE

EHA Library, Lauren Foster, 216488

EFFECT OF COMPOUND KUSHEN INJECTION ON IMMUNE FUNCTION FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING CHEMOTHERAPY

EHA Library, Honglei Tu, 216489

EFFICACY AND SAFETY OF TREATMENT WITH BORTEZOMIB,CYCLOPHOSPHAMIDE,DEXAMETHASONE （VCD) VERSUS BORTEZOMIB,DEXAMETHASONE(VD) REGIMENS IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA(NDMM)

EHA Library, Ma Liangming, 216490

BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION THERAPY IS COMPARABLE TO BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A SINGLE CENTRE EXPERIENCE

EHA Library, Firas Al-Kaisi, 216491

PROGNOSTIC SIGNIFICANCE OF THE REVISED INTERNATIONAL STAGING SYSTEM IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Jelena Bila, 216492

KRD TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL LIFE EXPERIENCE

EHA Library, Gregorio Barilà, 216493

THE AUTOPHAGY INHIBITOR HYDROXYCHLOROQUINE ADDED TO THALIDOMIDE BASED THERAPY FOR MULTIPLE MYELOMA DEEPENS RESPONSE AND PROLONGS REMISSION IN PATIENTS PREVIOUSLY TREATED WITH THALIDOMIDE.

EHA Library, Stephen O'Mara, 216494

PROGNOSTIC ROLE OF NEUTROPHIL-LYMPHOCYTE RATIO IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Alexander Luchinin, 216495

FACTORS ASSOCIATED WITH RENAL FAILURE AND RENAL FUNCTION RECOVERY IN MULTIPLE MYELOMA

EHA Library, Aysun SENTURK YIKILMAZ, 216496

AUTOLOGOUS TRANSPLANTATION WITH REDUCED PRE-TRANSPLANT CONDITIONING IN PATIENTS WITH MULTIPLE MYELOMA AT A HIGHER AGE - TOXICITY VERSUS EFFICACY.

EHA Library, Alexandra JUNGOVA, 216497

LENALIDOMIDE MAINTENANCE CHEMOTHERAPY; AN ANALYSIS OF REAL WORLD SURVIVAL DATA IN MULTIPLE MYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANT AND BORTEZOMIB-BASED INDUCTION

EHA Library, Hannah Cherniawsky, 216498

COMPARING EFFICACY OF INITIAL INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA. A VALUABLE INFORMATION IN POPULATION-BASED REGISTRIES

EHA Library, Rafael Rios-Tamayo, 216499

AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE

EHA Library, Tamara Berno, 216500

URINARY RETINAL BINDING PROTEIN IN UNTREATED SYSTEMIC IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS AT BASELINE.

EHA Library, Tamer Rezk, 216501

CLINICAL EFFICACY AND SAFETY OF LENALIDOMIDE IN NHS GREATER GLASGOW & CLYDE

EHA Library, Louis Doherty, 216502

EVALUATION OF PULMONARY FUNCTION TESTS IN PATIENTS WITH MYELOMA REVEALS THAT PULMONARY ABNORMALITIES ARE COMMON AND ARE INDEPENDENTLY ASSOCIATED WITH WORSE OUTCOME

EHA Library, Efstathios Kastritis, 216503

POSSIBLE FACTORS OF PROGRESSION IN MONOCLONAL GAMMOPATHY IN PATIENTS OF GOMEL REGION IN BELARUS

EHA Library, Zhanna Kozich, 216504

EFFECT OF BISPHOSPHONATE AND ANTI-MYELOMA THERAPY ON BONE TURNOVER MARKERS IN MULTIPLE MYELOMA

EHA Library, Aditya Jandial, 216505

HOW RUXOLITINIB IMPACTS ON DRIVER AND ADDITIVE MUTATIONS IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Sara Galimberti, 216508

TUMOR-SPECIFIC METHYLATION OF THE CANDIDATE TUMOR SUPPRESSOR GENE HLS5 IS AN EPIGENETIC BIOMARKER FOR ACUTE MYELOID LEUKEMIA(AML) AND MYELOPROLIFERATIVE NEOPLASM(MPN)

EHA Library, Jian Huang, 216509

A NOVEL GERMLINE CARL MUTATION AFFECTING AN EVOLUTIONARY CONSERVED REGION OF 3’UTR IN JAK2-NEGATIVE SIBLINGS WITH POLYCYTHEMIA VERA

EHA Library, Alberto Quattrocchi, 216510

HIGHER SCLEROSTIN/SOST EXPRESSION IS ASSOCIATED WITH LOWER PERCENTAGE OF CIRCULATORY BLASTS AND BETTER PROGNOSIS IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Marko Lucijanic, 216511

TET2 MUTATION IN CELLULAR REPROGRAMMING AND HEMATOPOIETIC DIFFERENTIATION

EHA Library, barbara monte mor, 216512

CALRETICULIN AND CD47 EXPRESSION IN A MDS/MPN CELL LINE MODEL K562: A MODEL FOR OUTCOME OF THERAPEUTIC RESPONSE

EHA Library, Kristian BOASMAN, 216513

MUTATIONAL PROFILES AND PHENOTYPIC FEATURES IN JAK2 V617F-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS – A SINGLE CENTRE EXPERIENCE

EHA Library, Gee Fung How, 216514

INFLAMMATION THROUGH MATRIX METALLOPROTEINASE IN MYELOPROLIFERATIVE NEOPLASM

EHA Library, Marijana Kovacic, 216516

THE MOLECULAR PATHOGENESIS AND THE HEMATOLOGICAL AND CLINICAL ASPECTS OF DRIVER AND SPLICEOSOME MUTATIONS IN POLISH PATIENTS WITH PRIMARY MYELOFIBROSIS.

EHA Library, Alicja Bartoszewska-Kubiak, 216517

MOLECULAR CHARACTERIZATION OF MYELOPROLIFERATIVE NEOPLASMS IN RUSSIAN COHORT OF PEDIATRIC PATIENTS

EHA Library, Marina Gaskova, 216518

GENE EXPRESSION PROFILE IN ESSENTIAL THROMBOCYTHEMIA: FINDING NEW MARKERS FOR TRIPLE NEGATIVE CASES

EHA Library, Santiago Sánchez Sosa, 216519

CURCUMIN: A NEW THERAPEUTIC STRATEGY FOR JAK2 V617F MUTATED CELLS

EHA Library, Jessica Petiti, 216521

BONE MARROW TRYPTASE LEVEL EVALUATION IN SISTEMIC MASTOCYTOSIS: ROLE IN DIAGNOSIS AND CLASSIFICATION OF DISEASE.

EHA Library, Michela Rondoni, 216522

CLINICAL EXOME SEQUENCING REVEALS HOMOZYGOUS VARIANT IN THE RASOPATHY GENE CBL IN A PEDIATRIC PATIENT WITH JUVENILE MYELO-MONOCYTIC LEUKEMIA: A CASE REPORT WITH COMPLEX GENETIC SPECTRUM

EHA Library, Abdul Ali Peer Zada, 216523

CD271+ MSCS IN MYELOPROLIFERATIVE NEOPLASMS PH-NEGATIVE

EHA Library, Marta Sobas, 216524

IDENTIFICATION OF NEW CALR AND ASXL1 MUTATIONS IN PATIENTS WITH MYELOFIBROSIS BY TARGETED NGS PANEL

EHA Library, Tatiana Subbotina, 216525

A HITHERTO UNDESCRIBED VHL SINGLE NUCLEOTIDE POLYMORPHISM INDUCED/RELATED POLYCYTHAEMIA ENTITY, CLINICAL FEATURES AND FAMILIAR CHARACTERISTICS. CLINICAL APPROACH

EHA Library, Miklos Udvardy, 216526

THE SPECTRUM OF THROMBOSIS IN POLYCYTHEMIA VERA: EXPERIENCE OF A TERTIARY HOSPITAL.

EHA Library, Sunil Lakhwani, 216527

ESSENTIAL THROMBOCYTOSIS IN CHILDREN

EHA Library, Canan Albayrak, 216528

COEXISTENCE OF JAK2V617F AND CALR MUTATIONS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA IN A SINGLE CENTER.

EHA Library, Maria Saez-Perdomo, 216529

THE EPIDEMIOLOGY AND PRESENTING CLINICAL CHARACTERISTICS OF MYELOPROLIFERATIVE NEOPLASMS IN MALAYSIA

EHA Library, Yee Yee Yap, 216530

THE MORTALITY OUTCOMES AND SURVIVAL PATTERNS OF MPN REGISTRY IN MALAYSIA

EHA Library, Yee Yee Yap, 216531

SECONDARY MALIGNANCIES IN BCR-ABL NEGATIVE CHRONIC MYELOPROLIFERATIVE DISEASES

EHA Library, Eren Arslan Davulcu, 216532

INTRODUCTION OF AN NGS GENE PANEL INTO CLINICAL SERVICE FOR MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Anna Skowronska, 216533

THERAPY OF PATIENTS WITH PREFIBROTIC STAGE OF PRIMARY MYELOFIBROSIS: LONG-TERM EFFECTS.

EHA Library, Eva Burnasheva, 216534

THIOL – DISULPHIDE HOMEOSTASIS IN POLYCYTHEMIA VERA

EHA Library, Aysun SENTURK YIKILMAZ, 216535

EFFICACY AND SAFETY OF RUXOLITINIB IN 132 TURKISH PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER AND RETROSPECTIVE ANALYSIS

EHA Library, Guray Saydam, 216536

BLOOD AND BONE MARROW CULTURES FOR THE DIAGNOSIS AND MANAGEMENT OF PRIMARY MYELOFIBROSIS

EHA Library, Tamar Saralidze, 216538